Swiss peptide CDMO · Dielsdorf, Switzerland
Theranostics
SENN, your cGMP partner for theranostics
Before the radioactivity comes the chemistry. Every radiopharmaceutical starts as a non-radioactive precursor: the targeting vector, linker and chelating motif that later meets the radionuclide. SENN develops and manufactures peptide-based and modified amino acid-based precursors for PET, SPECT and radioligand therapy programs, from route design through Phase I-III and commercial supply.
Backed by more than 60 years of peptide chemistry and process development expertise.
Built for nuclear medicine scale
Our scope: the precursor
SENN develops and manufactures the non-radioactive precursor. This covers the targeting molecule, peptide or modified amino acid scaffold, linker and chelator, together with process development, purification, characterisation, cGMP manufacture, lyophilisation and agreed vial presentation.
Radiolabelling and final radiopharmaceutical drug product manufacturing take place downstream, at the sponsor's selected facility or through SENN's established labelling network. SENN does not handle radionuclides.
One precursor partner, three steps
Target and route
Peptide-based precursor route finding and process development, with chemistry and analytics developed in parallel.
SENN cGMP precursor
Small-scale manufacture, purification, characterisation and release.
Radiolabelling (downstream)
Isotope handling and labelling at the sponsor's facility or within an established network, for PET/SPECT diagnostics or radioligand therapy.
Chemistry and process capability
Peptide synthesis
SPPS, LPPS, TAPS and hybrid synthesis. The molecule, scale, impurity profile and final specification select the route, not a preferred technology.
Broad chemistry
Modified amino acids, peptide precursors and fragments, including cyclic structures formed by various cyclisation strategies, amino acid spacers and PEG linkers.
Metal-controlled processing
Chelators bind metals, which is useful at radiolabelling and unhelpful during manufacture. SENN designs processes to minimise unwanted trace metal contamination in chelator-functionalised molecules, including DOTA, DOTAGA, NOTA and N4, and assesses potential metal-contact points throughout the process.
Purification and drying
Process-integrated preparative HPLC, filtration, solvent removal and lyophilisation.
Small-scale cGMP laboratory
| Capability | Equipment / Configuration | Customer-Relevant Capacity |
|---|---|---|
| Parallel manufacturing | Independent production lines in separate safety hoods | 2 controlled production lines |
| Synthesis | Double-jacketed glass reactors | 250 mL–5 L |
| SPPS and isolation | Glass filter reactors | 250 mL–5 L |
| Purification | Preparative HPLC | 10, 20 and 30 cm ID columns |
| Lyophilisation | Batch lyophiliser | Up to 25 L / 2,000 vials |
| Final handling | Laminar-flow cabin | ISO Class 4 environment |
Clinical-ready aliquoting
Low-dose precursors recover best from a characterised homogeneous solution, dispensed by defined quantity and lyophilised directly in the final vial. SENN fills and lyophilises directly into ready-to-label vials, down to 100 µg per vial and up to 2,000 vials per batch, with cleanroom handling and packaging. Cryo-box shipping is available on request.
Lyophilisation development focuses on recovery, stability and reconstitution behaviour for the downstream labelling process.
Characterisation and release to specification
Release testing follows customer requirements, regulatory expectations and applicable pharmacopoeial standards. Testing covers chemical, elemental, physicochemical and microbiological attributes, as required. Analytical development runs alongside the chemistry to build a phase-appropriate control strategy that matures with your program.
Clinical and established precursor supply
SENN manufactures established or approved precursors and APIs to existing customer specifications and dossiers, supporting clinical programs, routine supply and lifecycle continuity. International shipments are supported with the corresponding quality, storage and customs documentation.
One is not born with experience, and in my profession I use it every day.
Who we support
Why work with SENN
One site from development to GMP.
The same Dielsdorf site supports route development and subsequent cGMP manufacture, which reduces technology transfer and redevelopment.
Infrastructure sized to the product.
Theranostic precursors need grams, not kilograms, with the same expectations for reproducibility, traceability and release. Our equipment matches that scale.
Early involvement pays off.
Chelator choice, linker design, radionuclide pairing and vial presentation all influence manufacturability. Bring us in before the process is locked.
Start a conversation
Need a precursor for a new or established nuclear medicine program? Discuss route, scale, specification, clinical stage and labelling hand-off with SENN.
To assess a new program, send us: structure, intended radionuclide and labelling concept, development phase, quantity, desired presentation, target specification and timeline.